Wegovy Pill vs Wegovy Injection: Which Is Better for UK Patients?

The Wegovy pill and the Wegovy injection are two forms of semaglutide being used for weight management in the UK, with both belonging to a class of medicines called GLP-1 receptor agonists. This article explores how oral semaglutide compares with subcutaneous injections, including how each option works, differences in administration, effectiveness, suitability for UK patients and how to access a private prescription.

Semaglutide is the active ingredient in both formats, although the way it is taken differs significantly. The Wegovy pill is a once-daily tablet, while the Wegovy injection is a once-weekly injection developed by Novo Nordisk. The tablet and injection have different administration routes, meaning patients may need to consider factors such as an overnight fast, timing around food and medicines, lifestyle habits and personal preferences when discussing treatment options with a prescriber.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the semaglutide tablet for weight management, following evidence showing its suitability for adults who meet specific eligibility criteria [1]. The tablet was approved by the MHRA on the 11th of June 2026 for adults with a Body Mass Index (BMI) of 30 or above, or a BMI between 27 and 30 with a weight-related health condition [2].

The role of semaglutide in weight management is also shaped by guidance from the National Institute for Health and Care Excellence (NICE). NICE's assessment of semaglutide for weight management considers its use within specialist weight management services and for a limited treatment period, which helps explain why access to oral semaglutide may currently involve private prescription routes for some patients.

Both forms of Wegovy are intended to be used alongside a reduced-calorie diet and increased physical activity. A prescriber can help determine whether the Wegovy pill or Wegovy injection is more appropriate based on medical history, treatment goals and individual circumstances.

In One Sentence

The Wegovy pill and Wegovy injection contain the same active ingredient, semaglutide, but the best option depends on whether a patient prefers a daily fasted tablet or a weekly injection and how each format fits their lifestyle.

Key Takeaways

• Do the pill and injection contain the same drug? 

Yes, both contain semaglutide, a GLP-1 receptor agonist that helps regulate appetite, food cravings and feelings of fullness, but they are taken differently.

• Which one causes more weight loss? 

Clinical trials show similar real-world weight loss figures, with oral semaglutide reporting 13.6% weight loss and injectable semaglutide reporting 14.9% weight loss when compared using treatment-policy analysis methods.

• What is the single biggest difference? 

The main difference is administration, with the Wegovy pill requiring an 8-hour fast and a 30-minute wait before eating or drinking, while the injection does not require fasting.

• Do I have to use needles with the pill? 

No, the Wegovy pill is needle-free and may be suitable for people who experience needle aversion or injection anxiety.

• Is one available on the NHS? 

Access depends on eligibility, local NHS services and NICE guidance, while some patients may access Wegovy through a private prescription after a suitable clinical assessment.

Wegovy Pill vs Injection: At-a-Glance Comparison

The Wegovy pill and Wegovy injection both use semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk, but they differ in dosage, administration method and daily routine requirements.

The difference in dose between the Wegovy pill and injection is related to how the medicine enters the body. The tablet requires a higher dose because oral absorption through the gastrointestinal tract is lower compared with subcutaneous delivery.

The Wegovy pill follows a titration schedule where the dose is gradually increased to help the body adjust. Dose escalation is important for reducing side effects and improving tolerability. The Wegovy injection also follows a dose escalation schedule, usually increasing gradually over several weeks before reaching the maintenance dose.

Clinical studies have evaluated both forms of semaglutide. The OASIS 4 trial investigated oral semaglutide 25mg, while the STEP 1 trial assessed subcutaneous semaglutide 2.4mg. Both studies measured weight loss compared with placebo and provided evidence for the effectiveness of semaglutide as part of a wider weight management plan.

The daily Wegovy pill requires careful timing because it must be taken after an overnight fast with a sip of water. The tablet should be swallowed whole and followed by a 30-minute waiting period. The injection offers more flexibility because it can be taken once weekly at any time of day, with or without food.

Do the Wegovy Pill and Injection Contain the Same Medicine?

Yes, the Wegovy pill and Wegovy injection contain the same medicine, semaglutide, which is a synthetic version of a naturally occurring gut hormone called glucagon-like peptide-1 (GLP-1).

Semaglutide works by acting on GLP-1 receptors throughout the body, including appetite centres in the brain. As an incretin-based medicine, it helps influence hunger signals, food cravings and feelings of satiety, which can support reduced calorie intake and weight loss.

Although the active ingredient is the same, the formulations are designed differently. The Wegovy injection delivers semaglutide directly through subcutaneous injection, allowing it to enter the bloodstream more efficiently. The Wegovy pill must pass through the stomach and gastrointestinal system, where absorption is more challenging.

The MHRA-approved Wegovy tablet provides a new oral option for adults who meet the criteria for weight management treatment. However, it should not be confused with Rybelsus, which is another oral semaglutide medicine licensed for type 2 diabetes rather than weight management.

The main reason the Wegovy pill requires a higher dose than the injection is that only a small amount of swallowed semaglutide reaches the bloodstream. The tablet formulation uses SNAC (salcaprozate sodium), an absorption enhancer designed to improve how semaglutide passes through the stomach lining.

According to the product information, the tablet needs to be taken correctly because absorption can be significantly reduced if the fasting instructions are not followed. Around only 1% of a swallowed dose is absorbed, making timing and administration particularly important [3].

Why is the Pill Dose So Much Higher Than the Injection?

The Wegovy pill requires a much higher dose than the Wegovy injection because oral semaglutide has lower bioavailability compared with semaglutide delivered through subcutaneous injection.

When a medicine is swallowed, it must travel through the gastrointestinal tract before reaching the bloodstream. In the case of the Wegovy pill, stomach acid, digestion, and the natural barriers of the stomach lining can reduce the amount of semaglutide absorbed. This is why the oral formulation contains SNAC (salcaprozate sodium), an absorption enhancer that helps protect semaglutide and improve its passage through the stomach lining.

The Wegovy injection avoids these challenges because it delivers semaglutide directly into the body through subcutaneous delivery. This allows a smaller dose to achieve the intended therapeutic effect.

The difference between the Wegovy pill and injection can sometimes cause confusion because other semaglutide medicines use different doses and indications. For example, Ozempic is a semaglutide injection licensed for type 2 diabetes, while Rybelsus is an oral semaglutide tablet also licensed for type 2 diabetes. These medicines should not be compared directly with Wegovy without considering their approved uses, doses and treatment goals.

The fasting requirements for the Wegovy pill are also linked to absorption. Taking the tablet after an 8-hour fast, with a small amount of water and waiting 30 minutes before food, drinks, or other oral medicines helps ensure the medicine can be absorbed effectively.

Is the Wegovy Tablet as Effective as the Injection?

The Wegovy pill and Wegovy injection appear to offer similar levels of weight loss when studied using comparable clinical trial methods, although the results come from separate studies rather than a direct head-to-head comparison.

OASIS 4 Trial

The OASIS 4 trial examined oral semaglutide 25mg over 64 weeks. Using a treatment-policy estimand, which reflects outcomes regardless of whether participants fully followed treatment, participants taking oral semaglutide achieved 13.6% weight loss compared with 2.2% with placebo. The on-treatment estimand, which considers participants who remained on treatment as planned, showed a higher figure of 16.6%. The findings were published in the New England Journal of Medicine as the OASIS 4 trial [4].

STEP 1 Trial

The STEP 1 trial assessed weekly subcutaneous semaglutide 2.4mg over 68 weeks [5]. Participants receiving semaglutide achieved 14.9% weight loss compared with 2.4% with placebo. The study also found that 86.4% of participants achieved at least 5% weight loss.

Because the studies used different groups of participants and different timeframes, they do not prove that one format is always more effective than the other. However, the available evidence suggests that both formats can provide clinically meaningful weight loss when combined with lifestyle changes, including a reduced-calorie diet and physical activity.

SELECT Trial

Both forms of semaglutide may also have wider metabolic benefits. The SELECT cardiovascular outcomes trial investigated semaglutide 2.4mg in adults with cardiovascular disease and overweight or obesity without diabetes [6]. The trial found a reduction in major adverse cardiovascular events (MACE) compared with placebo. The OASIS 4 trial also reported improvements in markers such as blood pressure, HbA1c and prediabetes outcomes. These findings should be discussed with a healthcare professional because suitability depends on individual health circumstances.

Why Do You Sometimes See a Higher Figure of 16.6% for the Pill?

The higher 16.6% weight loss figure for the Wegovy pill comes from an on-treatment estimand, rather than the treatment-policy estimand used for the main comparison.

An on-treatment estimand looks at outcomes among people who continued taking the medicine according to the study plan. A treatment-policy estimand is closer to an intention-to-treat analysis because it includes participants regardless of treatment changes or interruptions.

In everyday use, real-world weight loss figures may vary because results depend on factors such as adherence, treatment consistency, reduced-calorie diet, physical activity and individual response to semaglutide.

Semaglutide treatment may also cause side effects that affect tolerability. Common gastrointestinal side effects can include nausea, diarrhoea, constipation and vomiting. In the OASIS 4 trial, serious adverse events were reported less frequently in the oral semaglutide group than in the placebo group.

“Clinical trial results provide important evidence about how semaglutide works under controlled conditions, but real-world outcomes can differ. Consistent treatment use, following administration instructions and maintaining healthy lifestyle changes all play an important role in achieving sustainable weight loss.” 

Daily Pill or Weekly Jab: How Does Each Fit Your Routine?

The biggest practical difference between the Wegovy pill and Wegovy injection is how each fits into a person’s daily routine, lifestyle and ability to maintain consistent dosing.

The Wegovy pill requires daily dosing and a structured morning routine. The Wegovy injection requires weekly dosing, which some people find easier to remember and manage.

The Wegovy Pill Routine (Daily)

The Wegovy pill must be taken on an empty stomach after an 8-hour fast, often following an overnight fast.

The tablet should be swallowed whole with no more than 120ml of water. It should not be split, crushed or chewed. After taking the tablet, patients must wait 30 minutes before eating, drinking coffee, taking other oral medicines or having other drinks.

This routine is important because food, drinks and other medicines can affect absorption. Taking the tablet at the same time each day can help improve consistency and support adherence.

For some people, this daily structure may fit naturally into their morning routine. For others, remembering the fasting window and 30-minute waiting period may feel more difficult, particularly if mornings involve commuting, childcare or an unpredictable schedule.

“The Wegovy pill routine works best when it becomes part of an established morning habit. The fasting window and 30-minute wait are important because they help the body absorb semaglutide properly. Building consistency around the routine can support adherence and long-term behaviour change.”

The Wegovy Injection Routine (Weekly)

The Wegovy injection is taken once weekly on the same day each week and can be administered at any time of day, with or without food.

The pre-filled pen delivers semaglutide through a subcutaneous injection into areas such as the abdomen, thigh or upper arm. Patients should rotate injection sites to reduce irritation.

The Wegovy injection device is known as the FlexTouch pen. Weekly dosing means some people find it easier to fit around work, travel and other lifestyle commitments because there is no daily fasting requirement.

The injection may be more suitable for people who prefer a low-effort routine or who have unpredictable schedules. However, some people may experience needle anxiety or prefer a needle-free option.

Storage, Travel and Discretion

The storage requirements of Wegovy pill and Wegovy injection are different, which can affect convenience when travelling or managing treatment discreetly.

The Wegovy pill offers greater portability because tablets can generally be stored at room temperature and carried more easily when away from home. This may suit people who travel regularly or prefer a discreet tablet-based treatment option.

The Wegovy injection requires more careful storage because the pre-filled pen must be kept refrigerated before use [7]. The injection needs refrigeration between 2 and 8°C to maintain product stability. This means patients may need to consider cold chain requirements when travelling or storing their medication away from home.

Once prepared for use, the injection has specific storage instructions and should be handled according to the product information. Patients should always follow the advice provided with their prescription and speak to a pharmacist or prescriber if they are unsure how to store or transport their medication.

The differences in storage can influence personal preference. A person who values shelf stability, portability and discretion may prefer a tablet, while someone comfortable managing refrigeration may prefer the convenience of weekly dosing.

Which Should You Choose: The Pill or the Injection?

The best choice between the Wegovy pill and Wegovy injection depends on individual circumstances, clinical suitability and personal preference rather than one option being universally better.

A prescriber can help assess factors such as medical history, treatment goals, lifestyle, ability to follow administration instructions and preferences around tablets or injections. Shared decision-making allows patients and healthcare professionals to choose an option that is realistic and sustainable.

The Wegovy Pill May Suit You If You:

The Wegovy pill may be suitable if you prefer a needle-free option and can comfortably follow the daily administration routine.

You may prefer the Wegovy pill if you have needle phobia, difficulty with injecting or simply prefer taking a tablet rather than using a pre-filled pen. It may also suit people who already have a consistent morning routine and can manage the fasting window, 8-hour fast and 30-minute wait before eating or drinking.

The tablet format may also be appealing for people who travel frequently and want a discreet medication option that does not involve carrying injection equipment or managing refrigeration.

However, the daily commitment is an important consideration. The effectiveness of oral semaglutide depends on taking it correctly and consistently to support absorption and treatment outcomes.

The Wegovy Injection May Suit You If You:

The Wegovy injection may be suitable if you prefer a simple weekly dosing schedule with fewer regular administration steps.

A weekly injection can be easier for people with unpredictable schedules because it does not require a fasting window or specific timing around meals. The treatment may fit better into a lifestyle where daily medication routines are difficult to maintain.

Some patients may also compare Wegovy injection with other injectable weight management medicines, including Mounjaro, which contains tirzepatide. In the United States, tirzepatide is also available under the weight-loss brand name Zepbound. These medicines work differently from semaglutide and require their own clinical assessment.

The Wegovy injection may be preferred by people who want a stable weekly routine and do not want to manage daily tablet timing. However, it may not be the preferred option for people who feel uncomfortable with needles.

Can You Switch From the Wegovy Injection to the Pill?

Switching between the Wegovy injection and Wegovy pill may be possible for some patients, but it should always be planned with a prescriber.

The MHRA confirms that patients taking the 2.4mg weekly injection can transition directly to the 25mg daily tablet without restarting the full titration process in appropriate circumstances [1]. However, individual treatment plans may differ depending on tolerance, medical history and previous response to semaglutide.

Although both formats contain the same active ingredient, the administration route changes how the medicine enters the body. A prescriber may consider factors such as appetite control, side effects, treatment goals and whether the patient has tolerated semaglutide well before recommending a switch.

Dose titration remains an important part of semaglutide treatment. The aim is to help the body adjust gradually and support treatment continuity while reducing the likelihood of unwanted side effects.

Patients should not switch between semaglutide products without medical guidance because taking duplicate doses could increase the risk of side effects.

“Moving from the injection to the tablet is not simply a change in routine. A prescriber should consider how someone has responded to semaglutide, whether they have tolerated the medicine and which format is most realistic for long-term use. An individualised plan supports safer treatment decisions.”

How to Access the Wegovy Pill or Injection in the UK

The Wegovy pill and Wegovy injection are prescription-only medicines, meaning they require a clinical assessment before treatment can begin.

The MHRA marketing authorisation for the semaglutide tablet was granted on the 11th of June 2026 for adults who meet specific eligibility criteria, including a BMI of 30 or above or a BMI between 27 and 30 with a weight-related comorbidity [1].

NHS

Access through the NHS depends on eligibility, local commissioning arrangements and NICE recommendations. NICE guidance has assessed semaglutide for weight management within specialist weight management services, which influences how treatment is provided.

Private Service

Some patients may choose to access Wegovy through a private prescription service. A suitable online prescription service, such as UK Meds, should include a consultation with a registered independent prescriber, assessment of Body Mass Index (BMI), review of relevant health information and clinical decision-making before treatment is supplied.

If treatment is approved, medication may be dispensed through a partner pharmacy registered with the General Pharmaceutical Council (GPhC). Patients should only use regulated healthcare providers that follow appropriate prescribing and dispensing standards.

The decision to prescribe Wegovy depends on whether the medicine is clinically appropriate. Factors such as weight-related health conditions, previous treatments, medical history and lifestyle considerations may all be reviewed during the consultation process.

Frequently Asked Questions

Is the Wegovy Tablet the Same as Rybelsus?

The Wegovy tablet and Rybelsus both contain semaglutide, but they are different medicines with different licensed indications.

Rybelsus is an oral semaglutide medicine developed by Novo Nordisk and is licensed only for type 2 diabetes [8]. It has a maximum licensed dose of 14mg. The Wegovy pill has a separate licensed indication.

Although both medicines use oral semaglutide, they should not be considered interchangeable because they are approved for different purposes and follow different treatment pathways.

Does the Wegovy Pill Need to Be Kept in the Fridge?

No, the Wegovy pill does not require refrigeration in the same way as the injection.

The tablet is easier to transport because it does not rely on the same cold chain requirements as the pre-filled pen. The Wegovy injection must be stored according to its refrigeration instructions before use.

Is the Pill or the Injection More Effective for Weight Loss?

Both Wegovy formats show similar weight loss outcomes in clinical trials, although the studies were conducted separately.

The OASIS 4 trial reported treatment-policy weight loss of 13.6% for oral semaglutide 25mg, while the STEP 1 trial reported 14.9% weight loss for weekly injectable semaglutide 2.4mg.

These figures should be viewed alongside factors such as adherence, lifestyle changes and whether the treatment fits a person’s routine.

Can I Take the Wegovy Pill and Injection at the Same Time?

No, the Wegovy pill and Wegovy injection should not be taken together unless specifically advised by a healthcare professional.

Both treatments contain semaglutide, so using both at the same time could result in semaglutide duplication. This may increase the overall dose received and could raise the risk of side effects, including gastrointestinal symptoms such as nausea, vomiting, diarrhoea and constipation.

A prescriber will consider the correct dose, treatment history and individual health circumstances before recommending any changes to semaglutide treatment. Patients should not combine, switch or adjust semaglutide medicines without medical advice.

Why Does the Pill Have a Fasting Rule but the Injection Does Not?

The Wegovy pill has a fasting rule because oral semaglutide must be absorbed through the stomach lining before entering the bloodstream.

Food, drinks and other oral medicines can affect absorption, which is why the tablet must be taken after an 8-hour fast with a small amount of water and followed by a 30-minute waiting period before eating or drinking.

The Wegovy injection does not have the same restriction because subcutaneous delivery bypasses the digestive system. The medicine is delivered under the skin rather than passing through the stomach and gastrointestinal tract.

This difference in bioavailability is the main reason why the Wegovy pill requires a higher dose than the injection.

Will I Lose the Weight I Gained Back If I Stop Either Format?

Weight regain can happen after stopping semaglutide because the effects on appetite, hunger signals and food intake may reduce once treatment ends.

GLP-1 medicines such as semaglutide help regulate appetite and support long-term weight management while they are being used. When treatment stops, appetite may return and maintaining previous weight loss can become more challenging without ongoing lifestyle support.

Research has shown that weight regain is common after stopping any GLP-1 medicine [9]. In studies following people after stopping semaglutide, participants regained around two-thirds of their previous weight loss within a year, highlighting the importance of long-term planning.

However, weight maintenance varies between individuals. Continuing healthy habits, including a reduced-calorie diet, regular physical activity and ongoing support from healthcare professionals, can help maintain progress.

Evidence from longer-term studies also suggests that weight loss can be sustained over two years when semaglutide treatment is continued alongside lifestyle changes [10].

Final Thoughts from the UK Meds Clinical Team

“The Wegovy pill and Wegovy injection provide two different ways to use semaglutide for weight management, with each option offering potential advantages depending on individual needs and lifestyle.

Choosing between the two formats is not only about weight loss results but also about finding a treatment approach that can be followed consistently. The Wegovy pill offers a needle-free option but requires a daily commitment, including an 8-hour fast and a 30-minute wait before eating or drinking. The Wegovy injection offers weekly dosing and may be easier for people who prefer a simpler routine without daily tablet timing.

Both options should be used alongside a reduced-calorie diet and physical activity, with support from a prescriber who can assess suitability and provide personalised advice. A consultation can help determine whether the Wegovy pill or Wegovy injection is the most appropriate choice based on medical history, treatment preferences and long-term weight management goals.”

Sources

[1] First GLP-1 tablet for weight loss approved in the UK - GOV.UK

[2] Semaglutide for managing overweight and obesity | Guidance | NICE

[3] Wegovy 1.5 mg tablets - Summary of Product Characteristics (SmPC) - (emc) | 102344

[4] Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity | New England Journal of Medicine

[5] Once-Weekly Semaglutide in Adults with Overweight or Obesity | New England Journal of Medicine

[6] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | New England Journal of Medicine

[7] Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) | 13803

[8] Rybelsus 1.5 mg Tablet - Summary of Product Characteristics (SmPC) - (emc) | 101229

[9] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - Wilding - 2022 - Diabetes, Obesity and Metabolism

[10] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial - PMC